Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy — Stella

Home/Penile Cancer/Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy

View on ClinicalTrials.gov

Recruiting

Back to Penile Cancer trials

Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

Netherlands

NKI-AVL, Amsterdam

Key details

Sponsor

The Netherlands Cancer Institute

Enrollment target

~29 participants

Started

April 2023

Primary completion

August 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated October 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.